In the same study, patients with either renal cell carcinoma (RCC) or non-small cell lung cancer (NSCLC) harboring a high DC signature before treatment were more prone to respond to PD-L1 inhibition with atezolizumab. This evidence concerns the gene CD274 and non-small cell lung carcinoma.